Argus analyst John Staszak raised the firm’s price target on Centene to $99 from $95 and keeps a Buy rating on the shares, citing recent contract wins in North Carolina, management having raised guidance for the fourth time this year, and positive earnings surprises in six of the past seven quarters. The company has grown by acquiring other health plans and services and he expects further acquisitions, Staszak added.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CNC:
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Centene downgraded to Underperform from Neutral at BofA
- Centene completes divestiture of Magellan Rx to Prime Therapeutics
- CENTENE COMPLETES DIVESTITURE OF MAGELLAN RX
- Managed care company returns will be tough to keep replicating, WSJ says
